Activating EGFR mutations represent the most common druggable target in metastatic NSCLC with non-squamous histology and show a well-documented incidence, varying between 10% in the European population and more than 64% in the Asian population [2,7,8,9,10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.